DVAHealthcare · Medical Care FacilitiesThe 8 Wall Street analysts covering DaVita, Inc. hold a median 12-month price target of $220 — +21.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DaVita, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (59): Analysts have, on balance, been cutting their forecasts.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +21.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | TD Cowen | Upgrade | Buy | $201 → $220 |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | $250 → $215 |
| 5 Aug 2026 | Barclays | Maintains | Equal-Weight | $218 → $224 |
| 14 July 2026 | Truist Securities | Maintains | Hold | $205 → $250 |
| 14 July 2026 | Truist Securities | Maintains | Hold | — |
| 10 July 2026 | UBS | Maintains | Buy | $235 → $270 |
| 10 July 2026 | UBS | Maintains | Buy | — |
| 9 July 2026 | Barclays | Maintains | Equal-Weight | $194 → $218 |
| 9 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 11 May 2026 | TD Cowen | Maintains | Hold | — |
| 8 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 8 May 2026 | Truist Securities | Maintains | Hold | — |
| 7 May 2026 | UBS | Maintains | Buy | — |
| 6 May 2026 | Deutsche Bank | Upgrade | Buy | — |
| 4 Feb 2026 | UBS | Maintains | Buy | — |
| 3 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 3 Nov 2025 | TD Cowen | Maintains | Hold | — |
| 30 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
| 9 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
| 10 Sept 2025 | B of A Securities | Maintains | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DVA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, DaVita, Inc. returned +42.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 72% of US stocks
Cheaper than 8% of US stocks
Cheaper than 40% of US stocks
Higher than 39% of US stocks
Higher than 67% of US stocks
Higher than 38% of US stocks
Higher than 74% of US stocks
Higher than 63% of US stocks
Higher than 96% of US stocks
Higher than 87% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DaVita, Inc. has a market value of $11.6B and an enterprise value of $26.2B.
Revenue in the twelve months to 30 June 2026: $14.0B. The latest quarter grew 5.2% year on year.
Net income over the same four quarters: $1.2B, a 8.5% net margin.
Diluted earnings per share, trailing twelve months: $12.22.
Free cash flow in the twelve months to 30 June 2026: $1.6B.
DaVita, Inc. spent $1.6B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 15.4×; forward P/E: 10.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
DaVita, Inc. employs 78,000 people — $180K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DaVita, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
DaVita HealthCare (DVA) closed at $179.25 in the latest trading session, up 1.26% from the previous day.
Why it matters — DVA watchers may note the stock’s gain in the latest session.
Seeking Alpha rates DaVita Buy, citing a $220 12-month price target and saying the stock’s decline to $180 makes its buybacks more accretive. The excerpt says buybacks drive most EPS growth despite flat industry volumes and Medicare rate headwinds.
Why it matters — DVA watchers may weigh the article’s view that lower valuation improves the effectiveness of the company’s buyback program against the cited operating headwinds.
The article says DaVita benefits from growth in IKC, improving treatment economics and stronger formulary adoption, while payer-mix pressures and costs remain concerns.
Why it matters — DVA watchers may weigh the cited operational gains against ongoing payer-mix and cost pressures.
DaVita activated its emergency response plan ahead of Hurricane Isaias to help patients continue receiving dialysis and support affected communities. It urged kidney patients to confirm treatment schedules, prepare emergency supplies, and contact the company for assistance.
Why it matters — The response concerns continuity of DaVita’s dialysis services and patient support as severe weather approaches parts of the Gulf Coast and southeastern United States.
A Motley Fool article highlights American Express, the last remaining credit card stock in Berkshire Hathaway’s portfolio, and The New York Times Company, which it says is bucking the struggling newspaper-industry trend.
Why it matters — The excerpt does not mention DaVita or provide information directly relevant to DVA watchers.
The 8 Wall Street analysts covering DaVita, Inc. have a median 12-month price target of $220, with estimates ranging from $165 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering DaVita, Inc., 3 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks DaVita, Inc. 93 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, DaVita, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +21.7% from the last close, and Ticker Nerd's factor model ranks DaVita, Inc. 93 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DaVita, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $270 over the next 12 months.
DaVita, Inc. returned +42.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
DaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease.
The most recent item we track (Zacks Investment Research, 9 Oct 2026): "Why DaVita HealthCare (DVA) Outpaced the Stock Market Today". DaVita HealthCare (DVA) closed at $179.25 in the latest trading session, up 1.26% from the previous day.
DaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease. DaVita provides in-center hemodialysis, peritoneal dialysis, and home dialysis options, along with related clinical support and care coordination services. The company also operates integrated kidney care programs and offers ancillary services that support treatment management and patient care across the kidney health journey. With a large network of dialysis centers in the United States and international markets, DaVita plays a major role in delivering life-sustaining renal care and serving healthcare systems, insurers, and patients who require ongoing treatment.
CEO Mr. Javier J. Rodriguez · 78,000 employees · United States · https://www.davita.com
